Cisplatin Disrupts Proteasome Bounce-Back Effect through Suppressing ZEB1/Nfe2l1 in Cholangiocarcinoma

Cisplatin Disrupts Proteasome Bounce-Back Effect through Suppressing ZEB1/Nfe2l1 in Cholangiocarcinoma

Background: Bortezomib (BTZ) is a powerful proteasome inhibitor that has been approved for the treatment of haematologic malignancies. Its effectiveness has been assessed against different types of solid tumours. BTZ is ineffective in most solid tumours because of drug resistance, including cholangi...

Full description

Bibliographic Details
Main Authors: Yuancai Xiang, Man Jia, Yuan Gao, Fang Yang, Teng Wang, Rongyang Dai, Meng Wang, Hongming Miao
Format: Article
Language:English
Published: IMR Press 2024-03-01
Series:Frontiers in Bioscience-Landmark
Subjects:
cisplatin
bortezomib
nfe2l1
zeb1
cholangiocarcinoma
Online Access:https://www.imrpress.com/journal/FBL/29/3/10.31083/j.fbl2903106

Internet

https://www.imrpress.com/journal/FBL/29/3/10.31083/j.fbl2903106

Similar Items